癌症生物療法：科技與全球市場

全球癌症生物療法市場預計將從 2025 年的 1,570 億美元成長到 2030 年底的 2,250 億美元，預測期內複合年成長率為 7.5%。

單株抗體市場預計將從2025年的881億美元成長到2030年底的1,265億美元，預測期內複合年成長率為7.5%。 CAR-T細胞療法市場預計將從2025年的234億美元成長到2030年底的341億美元，預測期內複合年成長率為7.8%。

本報告考察了全球癌症生物療法市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

目錄

第1章執行摘要

• 市場展望
• 調查範圍
• 市場摘要
• 技術進步
• 市場動態與成長要素
• 細分市場分析
• 結論

第2章 市場概覽

• 概述和市場定義
• 主要作用機轉和方式
• 波特五力分析
• 宏觀經濟因素分析
• 人口老化加劇了癌症發生率和生物製藥的需求。
• 醫療成本和癌症藥物支出不斷上漲
• 美國關稅情景的影響
• 癌症生物製藥的定價策略
• 基於價值的定價
• 創新溢價
• 基於指標的定價
• 市場進入和分級定價
• 競爭基準化分析
• 癌症藥物費用
• 生物相似藥概述
• 生物相似藥與癌症藥物成本
• 印度和中國的生物相似藥
• 歐洲的生物相似藥
• 生物相似藥的問題

第3章 市場動態

• 市場動態
• 市場促進因素
• 全球癌症發生率不斷上升
• 免疫腫瘤學和標靶治療的進展
• 邁向個人化和精準醫療的步伐
• 市場限制
• 高昂的醫療費用
• 嚴格的生產和監管要求
• 市場機遇
• 擴大核准生物製藥的適應症
• 生物製藥生產技術進步

第4章：監理現狀

• 監管情景
• 概述
• 美國
• EU
• 日本
• 中國
• 印度
• 醫療保險覆蓋範圍和報銷

第5章 新興科技與發展

• 概述
• 新一代抗體藥物偶聯物（ADC）
• 雙特異性和多特異性抗體
• 新抗原和個人化癌症疫苗（mRNA和胜肽）
• 同種異體（現成）細胞療法
• 人工智慧在癌症生物療法的應用

第6章 市場區隔分析

• 細分市場分析
• 按產品類型分類的癌症生物療法市場分析
• 單株抗體
• 疫苗
• CAR-T細胞療法
• 癌症生長抑制劑
• 免疫查核點抑制劑
• 其他（造血因子、細胞激素）
• 按癌症類型分類的癌症生物療法市場分析
• 按癌症類型/部位分類的流行病學
• 肺癌
• 乳癌
• 大腸直腸癌
• 攝護腺癌
• 其他（血液、皮膚、卵巢、罕見癌症）
• 地理細分
• 生物相似藥市場（按地區分類）
• 市場規模及預測
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第7章：癌症臨床試驗和研發中的生物製藥

• 概述
• 公司主要在研藥物

第8章 競爭情勢

• 概述
• 癌症生物療法市場：主要企業

第9章附錄

• 調查方法
• 參考
• 簡稱
• 公司簡介
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BIONTECH SE
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC
• INCYTE
• INNATE PHARMA INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI

The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.

The monoclonal antibodies segment of biological therapies market for cancer is expected to grow from $88.1 billion in 2025 and is projected to reach $126.5 billion by the end of 2030, at a CAGR of 7.5% during the forecast period of 2025 to 2030.

The CAR T-cell therapy segment of biological therapies market for cancer is expected to grow from $23.4 billion in 2025 and is projected to reach $34.1 billion by the end of 2030, at a CAGR of 7.8% during the forecast period of 2025 to 2030.

Report Scope

This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.

The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.

Report Includes

• 43 data tables and 53 additional tables
• An analysis of the global markets for biological therapies for cancer treatment and related technologies
• Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
• Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
• Impact analysis of the U.S. tariff laws on the market
• Insights derived from Porter's Five Forces model, as well as global supply chain
• A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
• Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
• A relevant patent analysis, featuring key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Technological Advances
• Market Dynamics and Growth Factors
• Segmental Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Key Modalities and Mechanisms of Action
• Porter's Five Forces Model
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Competition in the Industry
• Threat of Substitutes
• Macroeconomic Factors Analysis
• Aging Population Driving Cancer Incidence and Demand for Biologics
• Rising Healthcare Expenditures and Oncology Drug Spending
• Impact of the U.S. Tariff Scenario
• Pricing Strategies for Cancer Biologics
• Value-Based Pricing
• Premium Pricing for Innovation
• Indication-Based Pricing
• Market Access and Tiered Pricing
• Competitive Benchmarking
• Cancer Drug Costs
• Overview of Biosimilars
• Biosimilars and Costs of Cancer Drugs
• Biosimilars in India and China
• Biosimilars in Europe
• Issues with Biosimilars

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Global Cancer Incidence
• Advances in Immuno-Oncology and Targeted Therapies
• Shift Towards Personalized and Precision Medicine
• Market Restraints
• High Treatment Costs
• Stringent Manufacturing and Regulatory Requirements
• Market Opportunities
• Expanding Indications for Approved Biologics
• Technological Advances in Biologics Manufacturing

Chapter 4 Regulatory Landscape

• Biological Therapies for Cancer Industry Regulatory Scenario
• Overview
• U.S.
• EU
• Japan
• China
• India
• Medicare Coverage and Reimbursement for Cancer Care

Chapter 5 Emerging Technologies and Developments

• Overview
• Next-Generation Antibody-Drug Conjugates (ADCs)
• Bispecific and Multispecific Antibodies
• Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
• Allogeneic ("Off-the-Shelf") Cell Therapies
• Artificial Intelligence (AI) in Biological Cancer Therapies

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis for Biological Therapies for Cancer by Product Type
• Monoclonal Antibodies
• Vaccines
• CAR T-cell Therapy
• Cancer Growth Blockers
• Immune Checkpoint Inhibitors
• Other (Blood Cell Growth Factors, Cytokines)
• Market Analysis of Biological Therapies for Cancer by Cancer Type
• Epidemiology by Cancer Type/Site
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Other (Blood, Skin, Ovarian, Rare Cancer)
• Geographic Breakdown
• Global Biosimilars Market by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Cancer Clinical Trials and Biologics in Development

• Overview
• Key Pipeline Drugs by Company

Chapter 8 Competitive Landscape

• Overview
• Biological Therapy for Cancer Market: Major Players

Chapter 9 Appendix

• Methodology
• References
• Abbreviations
• Company Profiles
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BIONTECH SE
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC
• INCYTE
• INNATE PHARMA INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI

List of Tables

• Summary Table : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 1 : Key Federal Health Insurance Programs in the U.S.
• Table 2 : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 3 : Monoclonal Antibodies Approved for Oncology
• Table 4 : Global Monoclonal Antibodies Therapy Market for Cancer, by Region, Through 2030
• Table 5 : Global Vaccines Therapy Market for Cancer, by Region, Through 2030
• Table 6 : Global CAR T-Cell Therapy Market for Cancer, by Region, Through 2030
• Table 7 : Global Cancer Growth Blockers Therapy Market for Cancer, by Region, Through 2030
• Table 8 : Immune Checkpoint Inhibitors Approved for Oncology
• Table 9 : Global Immune Checkpoint Inhibitors Therapy Market for Cancer, by Region, Through 2030
• Table 10 : Global Other Biological Therapies Market for Cancer, by Region, Through 2030
• Table 11 : Global Cancer Incidence, by Cancer Type/Site, 2022
• Table 12 : Global Biological Therapies Market for Cancer, by Cancer Type, Through 2030
• Table 13 : Global Biological Therapies Market for Lung Cancer, by Region, Through 2030
• Table 14 : Global Biological Therapies Market for Breast Cancer, by Region, Through 2030
• Table 15 : Global Biological Therapies Market for Colorectal Cancer, by Region, Through 2030
• Table 16 : Global Biological Therapies Market for Prostate Cancer, by Region, Through 2030
• Table 17 : Global Biological Therapies Market for Other (Blood, Skin, Ovarian, Rare Cancers) Cancers, by Region, Through 2030
• Table 18 : Global Biological Therapies Market for Cancer, by Region, Through 2030
• Table 19 : North American Biological Therapies Market for Cancer, by Country, Through 2030
• Table 20 : North American Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 21 : North American Biological Therapies Market for Cancer, by Cancer Type, Through 2030
• Table 22 : European Biological Therapies Market for Cancer, by Country, Through 2030
• Table 23 : European Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 24 : European Biological Therapies Market for Cancer, by Cancer Type, Through 2030
• Table 25 : Asia-Pacific Biological Therapies Market for Cancer, by Country, Through 2030
• Table 26 : Asia-Pacific Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 27 : Asia-Pacific Biological Therapies Market for Cancer, by Cancer Type, Through 2030
• Table 28 : Rest of the World Biological Therapies Market for Cancer, by Product Type, Through 2030
• Table 29 : Rest of the World Biological Therapies Market for Cancer, by Cancer Type, Through 2030
• Table 30 : Clinical Trials, by Cancer Type/Site and Phase, 2025
• Table 31 : Key Pipeline Cancer Biologics
• Table 32 : Sales of Blockbuster Biological Cancer Therapy Drugs, 2024
• Table 33 : Leading Biological Therapies for Cancer Companies, Strategic Developments, 2024-2025
• Table 34 : Information Sources for this Report
• Table 35 : Abbreviations Used in this Report
• Table 36 : Amgen Inc.: Company Snapshot
• Table 37 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 38 : Amgen Inc.: Product Portfolio
• Table 39 : Amgen Inc.: News/Key Developments, 2024-2025
• Table 40 : AstraZeneca: Company Snapshot
• Table 41 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 42 : AstraZeneca: Product Portfolio
• Table 43 : AstraZeneca: News/Key Developments, 2024-2025
• Table 44 : Bayer AG: Company Snapshot
• Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 46 : Bayer AG: Product Portfolio
• Table 47 : Bayer AG: News/Key Developments, 2024
• Table 48 : BioNTech SE: Company Snapshot
• Table 49 : BioNTech SE: Financial Performance, FY 2023 and 2024
• Table 50 : BioNTech SE: Product Portfolio
• Table 51 : BioNTech SE: News/Key Developments, 2024-2025
• Table 52 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 53 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 54 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 55 : Bristol-Myers Squibb Co.: News/Key Developments, 2024-2025
• Table 56 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 57 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 58 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 59 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
• Table 60 : Gsk Plc: Company Snapshot
• Table 61 : Gsk Plc: Financial Performance, FY 2023 and 2024
• Table 62 : Gsk Plc.: Product Portfolio
• Table 63 : Gsk Plc.: News/Key Developments, 2024-2025
• Table 64 : Incyte: Company Snapshot
• Table 65 : Incyte: Financial Performance, FY 2023 and 2024
• Table 66 : Incyte: Product Portfolio
• Table 67 : Incyte: News/Key Developments, 2025
• Table 68 : Innate Pharma Inc.: Company Snapshot
• Table 69 : Innate Pharma Inc.: Financial Performance, FY 2023 and 2024
• Table 70 : Innate Pharma Inc.: Product Portfolio
• Table 71 : Innate Pharma Inc.: News/Key Developments, 2024-2025
• Table 72 : Johnson & Johnson: Company Snapshot
• Table 73 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 74 : Johnson & Johnson: Product Portfolio
• Table 75 : Johnson & Johnson: News/Key Developments, 2025
• Table 76 : Lilly USA LLC: Company Snapshot
• Table 77 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
• Table 78 : Lilly USA LLC: Product Portfolio
• Table 79 : Lilly USA LLC: News/Key Developments, 2023-2024
• Table 80 : Merck & Co. Inc.: Company Snapshot
• Table 81 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 82 : Merck & Co. Inc.: Product Portfolio
• Table 83 : Merck & Co. Inc.: News/Key Developments, 2024-2025
• Table 84 : Novartis AG: Company Snapshot
• Table 85 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 86 : Novartis AG: Product Portfolio
• Table 87 : Novartis AG: News/Key Developments, 2024-2025
• Table 88 : Pfizer Inc.: Company Snapshot
• Table 89 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 90 : Pfizer Inc.: Product Portfolio
• Table 91 : Pfizer Inc.: News/Key Developments, 2025
• Table 92 : Sanofi: Company Snapshot
• Table 93 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 94 : Sanofi: Product Portfolio
• Table 95 : Sanofi: News/Key Developments, 2024-2025

List of Figures

• Summary Figure : Global Biological Therapies Market Shares for Cancer, by Product Type, 2024
• Figure 1 : Porter's Five Forces Analysis for the Biological Therapies for Cancer Market
• Figure 2 : Snapshot of the Market Dynamics for Biological Therapies for Cancer
• Figure 3 : Global Biological Therapies Market Shares for Cancer, by Product Type, 2024
• Figure 4 : Global Cancer Incidence in Males, by Type/Site, 2022
• Figure 5 : Global Cancer Incidence in Females, by Type/Site, 2022
• Figure 6 : Global Cancer Incidence, by Region, 2022
• Figure 7 : Global Biological Therapies Market Shares for Cancer, by Cancer Type, 2024
• Figure 8 : Global Biological Therapies Market Shares for Cancer, by Region, 2024
• Figure 9 : North American Biological Therapies Market Shares for Cancer, by Country, 2024
• Figure 10 : European Biological Therapies Market Shares for Cancer, by Country, 2024
• Figure 11 : Asia-Pacific Biological Therapies Market Shares for Cancer, by Country, 2024
• Figure 12 : Global Biological Therapy Market Shares for Cancer, by Key Manufacturers and Suppliers, 2024
• Figure 13 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 14 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 15 : Astrazeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 16 : Astrazeneca: Revenue Shares, by Country/Region, FY 2024
• Figure 17 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 18 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 19 : BioNTech SE: Revenue Shares, by Country/Region, FY 2024
• Figure 20 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 21 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 24 : Gsk Plc: Revenue Shares, by Business Unit, FY 2024
• Figure 25 : Gsk Plc: Revenue Shares, by Country/Region, FY 2024
• Figure 26 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
• Figure 27 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
• Figure 28 : Lilly USA LLC: Revenue Shares, by Country/Region, FY 2024
• Figure 29 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 30 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 31 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 32 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 33 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 34 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 35 : Sanofi: Revenue Shares, by Country/Region, FY 2024